Pre-treatment with prasugrel -- more risk, no benefit: ACCOAST

In patients with non-ST-elevation acute coronary syndrome, pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the new results.

Read the whole article on Science Daily

More from Science Daily